TFS Capital’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

TFS Capital’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-192	Closed	-$53K	–	1118
2015 Q1	$53K	Buy	+192	New	+$82.9K	0.01%	928
2014 Q4	–	Sell	-144	Closed	-$47K	–	1186
2014 Q3	$47K	Sell	144 -58	-29%	-$17K	﹤0.01%	1001
2014 Q2	$68K	Buy	+202	New	+$79.3K	0.01%	1071

Other funds holding DMK

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TFS Capital's DMK Position: Q2 2015 in Review

TFS Capital sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2015, closing a stake of 192 shares — an estimated $53K sold.

TFS Capital first reported a position in DMK in Q2 2014 and held it in 3 quarters. The position peaked at $68K in Q2 2014. 29 funds tracked by Wall St. Rank hold DMK as of Q2 2015.

TFS Capital reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2015 after selling out during the quarter.
TFS Capital sold 192 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2015, an estimated $53K.
TFS Capital first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2014 and held it in 3 quarters.
TFS Capital's DMK Pharmaceuticals Corporation Common Stock position peaked at $68K in Q2 2014.
29 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.